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Liver  allocation  policy  recently was modified to use the 
Model for End-Stage  Liver  Disease  (MELD) for patients 
with  chronic  liver  disease to stratify potential recipients 
according to risk for waitlist death. In this study,  a retro- 
spective  cohort  of 760 adult patients with  chronic  liver 
disease placed on the liver transplant waitlist between 
January 1995  and March  2001 and followed up for up  to 
74 months was studied to assess the ability of the MELD 
to predict  mortality  among  waitlisted  candidates  and  eval- 
uate the prognostic  importance  of  changes in MELD  score 
over  time. Serial MELD  scores  predicted waitlist mortality 
significantly better than baseline  MELD  scores or medical 
urgency status. Each unit of the  40-point MELD  score  was 
associated  with  a  22%  increased risk for waitlist death 
(P C .001), whereas medical urgency status was not a 
significant independent predictor. For  any  given  MELD 
score, the magnitude and direction  of  change in MELD 
score during  the previous 30 days  (AMELD)  was a  signif- 
icant independent  mortality predictor. Patients  with 
MELD  score  increases greater than 5 points  over 30 days 
had  a  threefold greater waitlist mortality risk than those 
for whom  MELD  scores  increased  more  gradually (P < 
.0001). We  conclude that mortality risk on  the liver trans- 
plant waitlist is  predicted  more  accurately  by serial MELD 
score  determinations than by  medical  urgency status or 
single MELD measurements. AMELD score over time 
reflects  progression  of  liver  disease and conveys important 
additional  prognostic  information that should be  consid- 
ered in the further evolution  of  national  liver allocation 
policy. (Liver TranspZ2003;9:12-18.) 
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M ortality risk  assessment  for patients with severe liver disease has been studied for almost four 
decades. Publication of  the  Child-Turcotte classifica- 
tion  in 1964,' which  described a risk  classification  sys- 
tem for cirrhotic patients undergoing surgical proce- 
dures, and its subsequent modification by Pugh,2 
yielded a practical and predictive index on mortality. 
Child-Turcotte-Pugh (CTP) score  has  been  used in  the 
United States  since 1997 as one criterion to  rank can- 
didates awaiting liver tran~plantation.~ However, con- 
cerns  recently  have  surfaced regarding the wide  range of 
disease  severity among patients with  chronic liver  dis- 
ease within each of the three broad categories of medical 
urgency defined by current national liver allocation pol- 
icy. One criticism of CTP score  is  its  use of such sub- 
jective criteria as hepatic encephalopathy and ascites. 
Given the grave imbalance between the pool of suitable 
recipients and available  cadaveric donors,* an objective 
and more accurate method has  been sought for ranking 
potential candidates according to waitlist mortality risk. 
Recent studies have documented the ability of a 
score based on a continuous disease severity scale to 
predict 3-month mortality in a cohort of patients 
undergoing transjugular intrahepatic portosystemic 
shunt  (TIPS) procedures for the  treatment  of variceal 
hemorrhage in cirrhotic patients.5~~ Initially termed the 
Mayo TIPS Model,  the investigators found four statis- 
tically  significant mortality predictors in a multivariable 
Cox model. Three were readily obtainable laboratory 
values: serum bilirubin level,  serum creatinine level, and 
prothrombin  time  international normalized ratio 
(INR). The fourth variable  was  cause of cirrhosis; non- 
alcoholic noncholestatic causes had increased mortality. 
A regression equation  with coefficients for each of  the 
four variables  was constructed. 
In their second report, Kamath et a16 slightly modi- 
fied their  model  (now termed the  Model for End-Stage 
Liver Disease [MELD]) and examined several patient 
populations to assess its generalizability to a range of 
patients with end-stage liver  disease. Although promis- 
ing, these studies relied on a MELD score determina- 
tion  at a single point  in each patient's course and  did 
not directly study a group of patients awaiting liver 
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transplantation.  These studies did  not address  changes 
in mortality risk  over time  or  the need to periodically 
reassess that risk during  the  longer  times  required for 
patients awaiting  a  donated liver. A recent  report exam- 
ined patients on  the liver waitlist with severe disease 
(status 2a) and  found  that  the  MELD was a  superior 
predictor of pretransplantation ventilator requirements 
and dialysis need compared with the CTP system.’ 
Another  study  found  that  the MELD was highly  pre- 
dictive of pretransplantation mortality in status 2a 
patients.* 
Given that liver allocation policy in the United 
States is targeted toward providing donated livers to 
patients with the greatest risk for waitlist mortality, 
analysis of updated MELD scores and mortality risk 
during  the entire interval that patients are on  the wait- 
list is an  important step in the  evaluation of the  MELD 
as a basis for liver allocation. This is especially so given 
the recent institution of MELD-based allocation. In 
addition to information gained from using  serial 
MELD scores, we hypothesized  that  the  direction  and 
magnitude of recent changes in  MELD scores  may  be 
independently associated with  mortality risk. We con- 
ducted  the  current  study of waitlisted liver transplant 
candidates to examine these  issues. 
Methods 
Study  Design  and  Data  Collection 
The University  of  Michigan  Institutional  Review  Board  (Ann 
Arbor,  MI)  approved  the  study  protocol. All adult liver  trans- 
plant  candidates  at  the  University  of  Michigan  Health System 
with  chronic liver  disease who were placed  on  the  national 
Organ  Procurement  and  Transplantation  Network  (OPTN) 
waitlist  for  the first time  between  January  1,  1995,  and  study 
closure on  March  13,  2001, were  eligible  for  inclusion  in the 
study.  Patients  with  acute  (fulminant) liver  failure  were 
excluded. Institutional databases were queried to acquire a 
data  set  consisting  of age,  sex,  race, underlying liver  disease, 
and  date  of  placement  on  the  waitlist. 
Medical urgency status designation used the system in 
effect during  the  study  period.  Until  July  1,  1997,  statuses  2, 
3, and 4 were  used  for candidates  with  chronic liver  disease 
who  required  continuous  hospitalization,  continuous  outpa- 
tient  care,  and  intermittent  outpatient  care, respectively. As of 
July  1,  1997,  a  semiquantitative  system based on  CTP score 
was used.  Status 4 patients  were  reassigned  to  status 3 (CTP 
score, 7 to lo). Status  2 was redefined.  Status 2b  required  a 
CTP score  of 10  or  greater or 7 points  plus specified compli- 
cations. Status 2a was reserved for patients who developed 
life-threatening complications, required intensive care unit 
care, and  had  a life expectancy  of 7 days or less. 
Each  patient’s  initial  waitlist  medical  urgency  status and 
all subsequent changes were recorded until the earliest of 
transplantation,  death, or continued  presence  on  the  waitlist 
on  March  13, 200 1.  For  patients  removed  from  the  waitlist 
for  reasons other  than  transplantation  or  death, we used data 
from  medical  records  supplemented by query  of  the Social 
Security  Administration  Death  Master File.9 Time  at risk was 
extended  up  to 30 days from  waitlist  removal  (not  to exceed 
the  study  end  date),  and  deaths  within 30 days of removal 
were counted as waitlist  deaths. 
MELD Score Calculations 
MELD scores were calculated using serum bilirubin level, 
serum  creatinine level, and  INR  according  to  Kamath  et a15 
0.957 X log(serum  creatinine) + 0.378 
X log(serum  bilirubin) + 1.120 X log(INR) 
Baseline  calculation  required all three  laboratory  components 
within 14 days of placement on the waitlist. Subsequent 
MELD calculations  were  made  whenever  one  or  more  labo- 
ratory  components  changed. Scores  were rounded  to  the  near- 
est tenth  and  multiplied by 10. Based on  previous  studies,  the 
coefficient  for  disease  cause was not used; laboratory  inputs 
and  MELD score  limits  were  performed  in  accordance  with 
the  current O P T N  liver  allocation  methods.10  Serum  biliru- 
bin, INR, or serum  creatinine  values less than  1.0 were  set  to 
1.0 to preclude negative scores. Serum creatinine level was 
capped  at 4.0. MELD scores  were capped  at  40. 
Waitlist  Survival  Modeling 
Odds  of  90-day  mortality were estimated  using  logistic regres- 
sion. The concordance c-statistic (area under the receiver 
operating  characteristic  curve  [AUC ROC]) also was gener- 
ated. Time-dependent Cox proportional hazard regression 
models also  were developed  to assess mortality risk with  cen- 
soring at transplantation. Models were adjusted for patient 
age, sex, race, and year of  placement on  the waitlist.  Diagnosis 
was not significantly  associated  with  mortality on  the  waitlist 
and thus was not included in regression models. Survival 
estimation was performed  using SAS, version 8.00 (SAS Inti- 
tute,  Cary,  NC). 
Changes  in  MELD  Score  Over 30-Day  Intervals 
The time-dependent  Cox  models  describe  mortality risk asso- 
ciated  with  a  particular  MELD score  calculated  at  any  time 
during the patient’s residence on the waitlist. However, a 
patient’s MELD score  may  change  over  time. T o  determine 
whether  proximate  changes  in  MELD score  influence  waitlist 
mortality  independent  of  the risk  associated with  the  current 
MELD score itself, the  slope  of  MELD scores during  the  30 
days  before  each MELD score was calculated  using  the  least 
quares  method,  starting  at  day  30  on  the  waitlist  (AMELD). 
AMELD  of zero occurs  when  the  slope  of  the r gression  line 
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describing  all  MELD  scores  in  the  30-day  period is zero. A 
positive AMELD occurs when MELD scores generally are 
increasing during the 30-day period, whereas a negative 
AMELD  occurs  when  MELD scores generally are decreasing. 
Validation of MELD  Coefficients 
Published  parameter  estimates for Cox model  regression  coef- 
ficients of the  MELD  equation  (given  previously)  were  com- 
pared  with  those  calculated  using  laboratory values from  the 
current  study  data set. 





Seven hundred sixty adult patients were  placed on the 
waitlist for the first time between January l ,  1995,  and 
March 13,200  1, with follow-up during this  same time. 
Table 1 lists demographic characteristics of the  patient 
population. There was a preponderance of men (60%) 
and whites (85%). Mean age at baseline was 49 IT 9 
years. The majority of patients had cirrhotic liver  dis- 
ease (78%)  or cholestatic disorders (15%).  During  the 
course of  the  study,  258 patients (34%) received a liver 
transplant and  190 patients (25%) died on the waitlist. 
A total of 8,235 MELD scores were available for the 
760 patients (mean,  10.9 * l  l .O [SDI MELD deter- 
minations per patient; interquartile range, 3 to  15). 
Validation of MELD  Coefficients 
Regression  coefficients for log  values of  the three 
MELD components were  statistically  significant (P < 
.OS) and within  the 95% confidence bands for the orig- 
inal published coefficients  (Fig. 1). 
Odds of 90-Day  Mortality  (Logistic  Regression) 
MELD scores 30 days  after placement on the waitlist 
were  used to estimate the  odds  of subsequent 90-day 
mortality (i.e., death on or before  day 120). Compared 
with a reference group  of patients with MELD scores 
between 0 and  10, survival among patients with higher 
MELD scores was significantly decreased (Table 2). 
The AUC ROC for this logistic  regression  model  was 
0.85. In a separate model, patients classified  as status 2b 
and (old) status 2 after 30 days on  the waitlist  were at 
significantly  increased  risk for subsequent 90-day mor- 
tality compared  with  the status 3 reference group (Table 
2). The  AUC  ROC for this model (0.77) was lower 
than for MELD score. Additional 90-day mortality 
analyses starting 60, 90,  and  180 days  after placement 
on the waitlist  yielded  similar  results (data not  shown). 
Too few patients were in status 2a at 30 days after 
INR 
Figure 1. Coefficients for compo- 
nents of the MELD score.  Regression 
coefficients for the log values of com- 
1.35 ponents  were  statistically  significant 
at the P = .05 level and within the 
estimated  confidence  bands for the 
original  published  coefficients (Malin- 
0 1  
&m choc  et d5 and  Kamath  et d6). 
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NOTE. No patient was in status  2a  at  day 30 after  placement on the  waitlist. AUC ROC values for MELD  and  status were 0.85 and 0.77, 
respectively. 
placement on the waitlist to permit  calculation of a risk 
estimate for this group. 
MELD Score  and Waitlist Status as Time- 
Dependent  Covariates (Cox Models) 
The relative  risk (RR) for waitlist death was estimated 
using two separate Cox models. First, we examined  the 
association of a single  baseline MELD score on day 30 
with waitlist death.  Here, baseline MELD score was a 
significant mortality  predictor  (Chi-square, 88.8; RR, 
l .  15 per unit increase in MELD score; P < .001). In 
the  second  model, all  available MELD scores during  the 
patient's residence on the waitlist were  used in  a  time- 
dependent  Cox  model.  Compared  with baseline 
MELD score, the time-dependent MELD score was 
much  more  predictive ofwaitlist mortality  (Chi-square, 
630.6; RR, 1.22  per  unit increase in  MELD 
score; P < .OOl). In  the time-dependent  model, risk for 
death was  associated with  updated MELD scores, and 
each  increase  of one  MELD  point was associated with  a 
22% increase in waitlist mortality. 
A separate  time-dependent analysis  also found  that 
waitlist status was significantly  associated with waitlist 
mortality risk (Table 3). Compared  with status 3, status 
2b was  associated with  a fivefold  increase in risk, and 
status 2a, with  an RR of 85.2 (P C .001). 
Finally, MELD score and waitlist status were tested 
together as time-dependent covariates in a  combined 
Cox regression model. As listed in Table 4, MELD 
score  was highly significant and associated with  a  wait- 
list mortality risk of 22% per  unit increase in MELD 
score. Waitlist status provided  no significant incremen- 
tal contribution  to risk for death after updated MELD 
scores  were accounted for in the  model. 
. , . ,  , I ,. , I I _ .  n , . ,  . . // , . v  . 
Covariate chi-square RR P 
MELD 545.05 1.22 < .oo 1 
Status 2a 0.02 0.94  .885
Status 2b 0.08 0.93  .7 2 
Status 2 (old) 0.03 0.95 358 
NOTE.  Current MELD score is a  significant  predictor of 
waitlist  mortality.  Medical  urgency  status is not a  signifi- 
cant mortality  predictor with MELD score  included in  the 
model. 
~~ 
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Figure 2. Independent  effect of the  slope of MELD  scores 
during  30-day  intervals  (AMELD) on waitlist  mortality. 
An increase of more  than  five  MELD points  during  any 
30-day  interval  (positive  AMELD) was associated  with a 
threefold  increase in  waitlist  mortality  risk  independent of 
the MELD score at the end of the interval (RR, 3.16; 
P c .0001). 
Change of MELD Score 
To determine  the effect of changes in MELD score over 
time for a given patient, the slope representing that 
change during  the 30 previous days  was studied 
(AMELD). The reference group for this analysis was 
composed of 30-day intervals in which modest changes 
from 0 to + 5  MELD score points were recorded, 
reflecting gradual worsening of liver  disease in the wait- 
list population. Decreasing MELD scores (negative 
AMELD)  during  the 30-day interval (slope < 0) were 
associated with  a slightly protective effect (slope < 0; 
RR, 0.76; P = 355; Fig. 2). Positive AMELD of more 
than 5 points  during 30 days (slope > 5 )  was accompa- 
nied by a  threefold greater risk for death  compared  with 
the reference group (slope > 5 ;  RR, 3.16; P < .0001). 
This effect was independent of and additive  to  the abso- 
lute  MELD score at  the end of each 30-day interval 
(current MELD; RR, 1.17; P < .001). 
Discussion 
Allocation of donor livers in  the  United States is guided 
primarily by  assessment of the risk of recipient  death in 
the absence of  a  transplant as part of the overall  goal to 
maximize overall transplant benefit. Until February 
2002,  stratification  of  candidates u ed medical urgency 
statuses that divided patients  into those with  acute (sta- 
tus 1)  and chronic  (status 2a, 2b, and 3) liver  disease.3 
Medical criteria associated with disease severity were 
used to assign patients  to  the  three chronic-disease sta- 
tus designations, and donor livers were allocated in 
descending  order of status on a  point system  based on 
blood  group  type compatibility and waiting time within 
defined  geographic areas  (local Organ Procurement Orga- 
nization [OPO], OPTN region, entire nation). 
Increasing recognition that, especially within sta- 
tuses 2b and 3, wide variations exist in degree of medical 
urgency prompted  the  application  of  the MELD to liver 
allocation. In part, the MELD creates a more finely 
granular allocation system (40 levels) than  the  chronic- 
disease status system (3 levels). However, data  concern- 
ing  the ability of the  MELD  to accurately predict liver 
waitlist mortality during the prolonged periods that 
patients  must wait for liver transplants has  been lacking 
and will be some time forthcoming from the newly 
enacted national system. 
Because the MELD was first developed as a  tool  to 
predict mortality after TIPS placement in cirrhotic 
patients, it is important to determine its predictive 
value for actual waitlisted patients who are awaiting 
liver transplantation. A recently published  study 
showed that  3-month  mortality  could be predicted by 
the MELD in patients who had a range of chronic 
hepatic disorders.6 That study suggested the  MELD is a 
generalizable tool for prognostication  in such patients, 
but  did  not directly test that hypothesis on a  population 
of waitlisted patients. 
We found  that baseline MELD scores  were  signifi- 
cantly associated with liver waitlist mortality  and 
MELD scores  were more predictive than medical status 
level. This  supports previous work6 and is consistent 
with the direction in which national liver allocation 
policy  has  been  evolving. 
Unfortunately,  a single MELD score determined  at 
the time of placement on the waitlist is unlikely to 
accurately reflect mortality risk  across a  patient's  entire 
residence on the list. Median  waiting  time for a liver 
transplant in the  United States is greater than 1 year,* 
and  the course of chronic liver  disease is progressive and 
unpredictable.  Thus,  the new national system provides 
for periodic  updates of MELD score for patients 
remaining on the waitlist. Availability of an existing 
longitudinal set of  data  in  the  current  study provided 
three ways to validate and extend  the  utility of MELD 
score as a  predictor  of waitlist mortality and hopefully 
to preview some  of  the effects that may be expected 
under  the new system. 
First, the  present  study  reports  the first analysis  of 
repeated MELD scores  over time  from  patients on the 
liver transplant waitlist and provides strong evidence 
that updated MELD scores are a significantly better 
predictor of waitlist mortality than waitlist status levels 
or baseline (nonupdated) MELD scores. Patients  in  the 
cohort  had  a mean of 1  1  MELD  determinations  during 
Liver  Transplant  Waitlist  Mortality Risk 17 
their residence on  the waitlist, corresponding to  1.85 
MELD scores  per month.  In  the  Cox  model  combining 
updated MELD scores and  updated waitlist status levels 
as covariates,  each point of the  40-point  MELD score 
was associated with  a  22% increased risk for waitlist 
death (P < .OOl),  whereas status level  was not  a signif- 
icant independent predictor. These results  are substan- 
tively in  support  of  the  current OPTN policy to man- 
date  periodic  updating of MELD scores and  provide 
additional evidence that  such  a practice may result in 
more  equitable allocation of donor livers in the  United 
States. 
Second, the Cox model based on University of 
Michigan data produced statistically significant and 
robust regression  coefficients for each of  the  three lab- 
oratory  components of the  MELD score. In  addition, 
these  regression  coefficients  were within  the  estimated 
confidence  bands for the original published coefficients. 
Because our  cohort is different from all others on which 
MELD scores  have  been  tested in the past, findings of 
this study  provide  further  validation f the utility of the 
MELD in predicting  pretransplantation mortality. 
Data collection from all waitlisted liver transplant  can- 
didates in the  United States is under way, and subse- 
quent analyses  will determine  whether  adjustments to 
the coefficients  are  necessary  over time. 
Third, our analyses clearly show that AMELD, a 
measure of the  magnitude  and  direction of change  in 
MELD score during  the previous 30 days,  is an  impor- 
tant  and  independent  predictor f  liver  waitlist mortal- 
ity. Patients  with  a positive AMELD greater than five 
during a 30-day period had more than a threefold 
greater waitlist mortality risk than patients for whom 
MELD scores  increased more gradually. Patients  with  a 
AMELD  of zero or negative AMELD  during  the pre- 
ceding 30 days had slightly lower mortality risk com- 
pared  with  the reference group.  Under  the initial 
MELD-based liver allocation system currently  imple- 
mented by the OPTN, allocation decisions among two 
or  more  candidates  with  the same MELD score  are to be 
adjudicated by comparing  the amount of waiting  time 
at  or above that score. Such patients would be  likely to 
have a negative 30-day  AMELD. In this circumstance, 
the existing tiebreaker rule  may incorrectly  order 
patients with  the same MELD score. 
For  example, suppose  there are three patients with 
identical MELD scores  (e.g., 20)  who are  eligible can- 
didates to receive a  donor liver today.  Patient A had two 
additional MELD scores of 20 during the previous 
month. Patient B had  a MELD score of 30  a  month 
previously, and a score of 25 two weeks previously. 
Thirty days  ago, patient C had  a MELD score of 10, 
and it increased to 15 two weeks  ago  before reaching its 
current level  of 20. In this set of patients, the existing 
allocation system  would  offer the liver  first to patient  B 
(based on most  ime L 20)  and  then  adjudicate 
between patients A and C solely on  the basis  of waiting 
time. However, the AMELD analysis  suggests that 
patient C actually  has the greatest predicted  mortality 
risk on  the basis of  a positive AMELD  of l0  points over 
30 days. Patient A has a zero 30-day AMELD and 
therefore  would be prioritized second under  a  AMELD 
mortality risk tiebreaker, and  patient  B  would be third 
in line for the  donor liver  because  of a negative 
AMELD.  Further analyses  using national  data are crit- 
ical to examine this issue and are under way. Incorpo- 
ration of AMELD as a  fourth  component  of  a modified 
MELD score  also should be considered. 
There are some limitations to the present study. 
Most  importantly,  patterns of pretransplantation  mor- 
tality and  transplantation will change as the  MELD- 
based  system is used  for organ allocation. All patients in 
the  current  study  underwent  transplantation  under  the 
existing  medical  status-  based allocation system. Thus, 
censoring at transplantation  would have  affected a dif- 
ferent set of patients had  the available donor organs 
been  allocated according to  MELD score.  For  example, 
some patients with  high MELD scores who  died  on  the 
waitlist would likely have undergone transplantation, 
whereas patients with  higher medical status with low 
MELD scores would have remained on  the waitlist for a 
longer  time.  Despite this, the  current  study offers  valu- 
able insight into  the effects of  changing MELD scores 
over time  in patients followed up  longitudinally  on  the 
waitlist. It will take several  years to accumulate similar 
longitudinal  data  at  the  national level. 
We have considered a methodological issue that 
could arise  because  of nonrandom  censoring because  we 
try to perform  transplantation in those at greatest  risk 
for death  and  then censor them at transplantation in the 
analysis.  If the sickest patients all  received a  transplant 
before death,  then waitlist mortality rates  clearly would 
be underestimated. However, under  the allocation sys- 
tem before February 2002 for patients with chronic 
liver disease (statuses 2a, 2b, and 3), there are geo- 
graphic  distribution features that allocate donor organs 
within  the local OPO area to lower  risk patients, pri- 
marily on  the basis  of waiting  time  rather  than severity. 
Regional and  national patients at greater  risk  have  lower 
priority than these  local patients. In addition,  a  donor 
liver is not always available on a timely basis for the 
highest status persons on  the waitlist. This results in 
substantial waitlist mortality for  high-risk patients and, 
unfortunately, prevents them from receiving a trans- 
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plant. These realities of  the previous allocation system 
mitigate  the effects  of nonrandom  censoring. 
Pediatric candidates for liver transplantation were 
not  included in the  study because  of  lack  of  sufficient 
data. Children  do  not have the same  risk for death on 
the waitlist as adults, and  separate analyses  have  been 
developed using a Pediatric End-Stage Liver Disease 
 SCOT^.^^,^^ 
Finally, patients with  fulminant liver failure (status 
1) also  were excluded. The  MELD score was developed 
for individuals  with  chronic liver  disease, so we  focused 
on these patients. Because the liver allocation system 
recently  made  operational by the OPTN retains status 1 
as a  separate allocation class and  only uses MELD-based 
allocation for those with chronic disease, the use of 
MELD scores to assess mortality risk among status 1 
patients will  be  possible once  enough  data have  been 
collected at  the  national level. 
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